Brokers Issue Forecasts for ZVRA FY2029 Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Investment analysts at Roth Capital issued their FY2029 EPS estimates for Zevra Therapeutics in a report issued on Sunday, February 9th. Roth Capital analyst J. Aschoff forecasts that the company will post earnings per share of $2.26 for the year. The consensus estimate for Zevra Therapeutics' current full-year earnings is ($1.95) per share.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.25). Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The firm had revenue of $3.70 million for the quarter, compared to analysts' expectations of $5.04 million. During the same quarter in the previous year, the business earned ($0.40) earnings per share.

A number of other analysts have also weighed in on ZVRA. Cantor Fitzgerald raised shares of Zevra Therapeutics to a "strong-buy" rating in a research note on Wednesday, January 29th. Canaccord Genuity Group dropped their price objective on shares of Zevra Therapeutics from $25.00 to $23.00 and set a "buy" rating on the stock in a research note on Thursday, November 14th. Finally, HC Wainwright reissued a "buy" rating and issued a $20.00 price objective on shares of Zevra Therapeutics in a research note on Wednesday, November 20th. Six research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Zevra Therapeutics presently has an average rating of "Buy" and an average price target of $21.57.

Zevra Therapeutics Stock Up 0.8 %

Shares of ZVRA traded up $0.07 during midday trading on Tuesday, reaching $8.06. 243,063 shares of the stock were exchanged, compared to its average volume of 402,061. The company has a market capitalization of $429.98 million, a P/E ratio of -4.09 and a beta of 2.00. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84. Zevra Therapeutics has a 52 week low of $4.20 and a 52 week high of $9.76. The company's 50 day moving average is $8.26 and its two-hundred day moving average is $8.03.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ZVRA. The Manufacturers Life Insurance Company grew its stake in shares of Zevra Therapeutics by 15.2% during the second quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company's stock worth $91,000 after acquiring an additional 2,452 shares during the last quarter. Sanctuary Advisors LLC acquired a new stake in Zevra Therapeutics in the 2nd quarter worth approximately $474,000. SG Americas Securities LLC purchased a new stake in Zevra Therapeutics during the 3rd quarter worth approximately $105,000. City State Bank increased its stake in Zevra Therapeutics by 14.1% during the 3rd quarter. City State Bank now owns 16,224 shares of the company's stock valued at $113,000 after purchasing an additional 2,000 shares in the last quarter. Finally, IFG Advisors LLC raised its holdings in shares of Zevra Therapeutics by 41.2% in the third quarter. IFG Advisors LLC now owns 26,400 shares of the company's stock worth $183,000 after buying an additional 7,700 shares during the last quarter. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.